Cargando…

Ocrelizumab does not impair B- and T-cell responses to primary VZV infection in a patient with MS

Detalles Bibliográficos
Autores principales:	Novi, Giovanni, Ivaldi, Federico, Sbragia, Elvira, Mikulska, Malgorzata, Pesce, Giampaola, Inglese, Matilde, Kerlero de Rosbo, Nicole, Uccelli, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Clinical/Scientific Notes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051194/ https://www.ncbi.nlm.nih.gov/pubmed/32098867 http://dx.doi.org/10.1212/NXI.0000000000000695

Ejemplares similares

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
por: Novi, Giovanni, et al.
Publicado: (2020)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Impact of treatment on cellular immunophenotype in MS: A cross-sectional study
por: Cellerino, Maria, et al.
Publicado: (2020)

Teriflunomide treatment reduces B cells in patients with MS
por: Gandoglia, Ilaria, et al.
Publicado: (2017)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells
por: Ferrara, Giovanni, et al.
Publicado: (2021)

VZV-associated acute retinal necrosis in a patient with MS treated with natalizumab
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2019)

Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS
por: Cellerino, Maria, et al.
Publicado: (2019)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Vaccinations in patients with multiple sclerosis: a real-world, single-center experience
por: Sbragia, Elvira, et al.
Publicado: (2022)

Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status
por: Carlini, Federico, et al.
Publicado: (2021)

VZV in biopsy-positive and -negative giant cell arteritis: Analysis of 100+ temporal arteries
por: Gilden, Don, et al.
Publicado: (2016)

Acute disseminated encephalomyelitis after SARS-CoV-2 infection
por: Novi, Giovanni, et al.
Publicado: (2020)

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
por: Tazza, F., et al.
Publicado: (2021)

Aseptic Neutrophilic Meningitis With Hypoglycorrhachia Following a Single Ocrelizumab Infusion
por: Cicero, Steven, et al.
Publicado: (2021)

Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response
por: Parodi, Benedetta, et al.
Publicado: (2021)

Tailoring B cell depletion therapy in MS according to memory B cell monitoring
por: Novi, Giovanni, et al.
Publicado: (2020)

NG2, a common denominator for neuroinflammation, blood–brain barrier alteration, and oligodendrocyte precursor response in EAE, plays a role in dendritic cell activation
por: Ferrara, Giovanni, et al.
Publicado: (2016)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease?
por: Parodi, Benedetta, et al.
Publicado: (2021)

The role of disconnection in explaining disability in multiple sclerosis
por: Lapucci, Caterina, et al.
Publicado: (2022)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Role of miRNAs shuttled by mesenchymal stem cell-derived small extracellular vesicles in modulating neuroinflammation
por: Giunti, Debora, et al.
Publicado: (2021)

Microparticle-mediated VZV propagation and endothelial activation: Mechanism of VZV vasculopathy
por: Eleftheriou, Despina, et al.
Publicado: (2020)

Neuroinflammation induces synaptic scaling through IL-1β-mediated activation of the transcriptional repressor REST/NRSF
por: Buffolo, Federica, et al.
Publicado: (2021)

Correction: Neuroinflammation induces synaptic scaling through IL-1β-mediated activation of the transcriptional repressor REST/NRSF
por: Buffolo, Federica, et al.
Publicado: (2023)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022)

Effect of Multiple Sclerosis and Its Treatments on Male Fertility: Cues for Future Research
por: Massarotti, Claudia, et al.
Publicado: (2021)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
por: Fernández-Velasco, José I., et al.
Publicado: (2021)

Varicella zoster virus (VZV)-specific immunity and subclinical VZV reactivation in patients with autoimmune diseases
por: Lee, Kwang-Hoon, et al.
Publicado: (2021)

Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
por: Fuchs, Vidmante, et al.
Publicado: (2021)

Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice
por: Girolamo, Francesco, et al.
Publicado: (2019)

Microglia-derived CCL2 has a prime role in neocortex neuroinflammation
por: Errede, Mariella, et al.
Publicado: (2022)

Enhancement of the Trigeminal Nerve by VZV Reactivation
por: Yaguchi, Hiroaki, et al.
Publicado: (2021)

Epstein-Barr–negative MS: a true phenomenon?
por: Dobson, Ruth, et al.
Publicado: (2017)

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod
por: de Jong, Brigit A., et al.
Publicado: (2018)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f08jg6b9o3e8s2psgvv9u7flha